Three Common Drugs Show Promise as Topical Anti-Aging Treatment in Small Trial

This phase 1 clinical trial explored an innovative approach to skin aging by testing three FDA-approved drugs as topical treatments. Researchers investigated whether sirolimus, metformin, and diclofenac could target age-related pathways when applied directly to skin, rather than taken systemically for their traditional uses.

The open-label, placebo-controlled study enrolled 10 healthy adult volunteers over nearly two years, from March 2017 to February 2019. Each participant received topical applications of the three-drug combination, allowing researchers to examine effects on skin aging markers and pathways.

The drug combination represents a strategic selection: sirolimus inhibits mTOR pathways linked to cellular aging, metformin activates AMPK and may extend cellular lifespan, while diclofenac reduces inflammation associated with aging processes. By applying these medications topically, researchers aimed to achieve localized anti-aging effects while minimizing systemic side effects.

While specific results weren't detailed in available information, the trial's completion suggests researchers successfully gathered safety and preliminary efficacy data. This represents important groundwork for understanding whether repurposed medications can effectively target skin aging when applied topically.

For longevity enthusiasts, this research highlights the potential of drug repurposing in anti-aging medicine. The approach of combining multiple agents targeting different aging pathways reflects current understanding that aging involves multiple interconnected processes. However, the small sample size means these findings require validation in larger studies before any clinical recommendations can be made.